DOCSLIB.ORG

Viagra) Tadalafil (Cialis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Viagra) Tadalafil (Cialis Erectile Dysfunction Primary Care Management Louis Kuritzky, MD Family Physician 4510 NW 17th Place Gainesville, Florida 32605 [email protected] Question #1 • Which of the following is NOT a risk factor for ED? A) Elevated LDL B) Elevated BP C) Elevated Uric Acid D) Reduced HDL Question #2 • A patient took vardenafil (Levitra) 36 hours ago, and is now having chest pain. Which is true about administering nitroglycerin? A) It is contraindicated B) The dose should be reduced C) A higher dose will be required D) No dosing/administration change is needed Question #3 • A 28 year old single, heterosexual male patient has psychogenic ED. The most likely contributing disorder is? A) Excess sympathetic drive B) Excess parasympathetic drive C) An exaggerated Oedipal Syndrome D) Madonna Prostitute Syndrome Question #4 • The use of vacuum constriction devices… A) May be associated with decreased penile temperature B) May be associated with increased penile temperature C) Is associated with decreased penile girth D) Is only appropriate for men over age 60 ED: Agenda • Why Bother • Scope of the Problem • Pathophysiology: Penodynamics • Definitions • Emotional Issues & ED • Obstacles to Rx • Rx WHY BOTHER Why Bother Erectile Endothelial Dysfunction Dysfunction ED Compelling Epidemiology Massachusetts Male Aging Study: Key Prevalence Study of ED Feldman HA et al. J Urol. 1994;151:54-61. Massachusetts Male Aging Study: Age-adjusted ED Progression 80 70 67% 60 57% 50 48% Prevalence 40 40% (%) 30 20 10 0 4040 5050 6060 7070 Age (y) Minimal ED Moderate ED Complete ED Adapted with permission from Feldman HA, Goldstein I, Hatzichristou DG et al. Impotence and its medical and psychosocial correlates: results from the Massachusetts Male Aging Study. J Urol. 1994;151(1):54Feldman-61. HA et al. J Urol. 1994;151:54-61. Impotence and DM • Frequency 35-75% • Age dependent AGE FREQUENCY 20-29 9% 30-34 15% 60-64 55% Bennett, Alan Impotence WB Saunders 1994 Chapter 1 ED: Major Modifiable Risk Factors • Hypertension • DM • Vaculopathy: (lipids, homocysteine) • Medications: HCTZ, Beta-blockers • Lifestyle: stress, fatigue • Toxins: smoking, alcohol Feldman HA et al. J Urol. 1994;151:54-61. Major Risk Factors for ED: Chronic Diseases Chronic Disease ED Age-adjusted O.R. Diabetes1,2 ×4.1 LUTS1 ×2.9 PAD1 ×2.6 Cardiac problems1 ×1.8 Hyperlipidemia1 ×1.7 Hypertension1,2 ×1.6 1. Martin-Morales A et al. J Urol. 2001;166:569-575. 2. Braun M et al. Int J Impot Res. 2000;12:305-311. Erectile Dysfunction (ED) Is a Vascular Disease1,2 Precursors Diabetes Dyslipidemia Hypertension Oxidative stress Tobacco Endothelial Vasoconstriction cell injury Atherosclerosis Erectile dysfunction Thrombosis Outcomes 1Dzau VJ, et al. Am J Cardiol. 1997;80(9A):33I-39I. 2NIH Consensus Development Panel on Impotence. JAMA. 1993; 270:83-90. Penodynamics The Physiology of the Erectile Process Tumescence 1. Stimulation Psychic or sensory 2. Neurotransmitter release 3. Smooth muscle relaxation 4. Arterial flow increase 5. Veno-occlusive function Tumescence : Primary Messengers (In Cavernosal Smooth Muscle) cGMP cAMP Prostaglandin Mechanism of Erection NANC NO Endothelial cells NANC Guanylate cyclase NO GTP Penile cGMP Relax erection GMP PDE5 cGMP = cyclic guanosine monophosphate; GTP = guanosine triphosphate; NANC = nonadrenergic-noncholinergic neurons; NO = nitric oxide; PDE5 = phosphodiesterase type 5. Adapted from Sadovsky R, et al. Int J Clin Pract. 2001;55:115-128. Erection Pathways: Endothelium & cGMP Parasympathetic stimulation (Acetylcholine) endothelium NO ↑ cGMP→ relaxation/dilation Corpora Cavernosa Vascular Smooth Muscle Cell Erection Pathways: Nitrergic NS & cGMP NANC (Non-adrenergic, Non-cholinergic NS) endothelium NO ↑ cGMP → relaxation/dilation Corpora Cavernosa Vascular Smooth Muscle Cell Erection Pathways: Nitrergic NS & cGMP Prostaglandins (ICI, urethral suppository) endothelium ↑ cAMP → relaxation/dilation Corpora Cavernosa Vascular Smooth Muscle Cell ED : Emotional Consequences & Comorbidities ED : Emotional Consequences & Comorbidities • Anxiety • Depression • Bruised Self-Esteem • Relationship Conflict • QOL decrement Male Sexual Function Master-Control Center AnatomyAnatomy ofof thethe MaleMale BrainBrain Female Sexual Function Master Control Center AnatomyAnatomyThe ofFemaleof thethe MaleMaleBrain BrainBrain Shoes Acquisition Complex Parallel parking center Need More Black Shoes Synapse Too Cold Maintenance Site High Heels Adaptation Glands Color Coordination Center Brad Pitt Appreciation Lobe Fart Appreciation Romance Lobes Molecule Candles (yellow) Flowers (blue) Increased Incidence of Depressive Symptoms in ED 60 ** ** 50 40 30 20 10 0 Incidence of depression (%) of depressionIncidence ED only BPH only ED + BPH N = 48 N = 34 N = 18 ** p < 0.005 Shabsigh et al. Urology. 1998;52:848-52. OBSTACLES Undertreatment of ED With permission McKinlayfrom McKinlay JB. Int J JB.Impot Res Int. 2000;12(suppl J Impot 4):S6-S11. Res Based on. data2000;12 from the Massachusetts (suppl Male Aging 4):S6 Study (MMAS).-S11. Source: AARP. Modern Maturity, Washington DC, 1999. Data from AARP Survey. Modern Maturity Magazine, Wash DC, 1999. Etiologies of Impotence in Seniors Etiology Frequency Neurologic and vascular 30.3% Vascular 21.1% DM neuropathy 17.1% Non-DM neuropathy 10.5% Psychological 9.2% Meds 3.9% ↓ TST 2.6% Peyronie’s disease 1.3% Unknown 4.1% Mulligan T. Arch Int Med. 1989;149:1365-1366 OBSTACLES The Top 10 Medical Conditions too Embarrassing for Patients to Discuss With Their Family Physician MA Preboth Am Fam Phys 1999;59(1):18 1. Impotence 2. STDs 3. Physical and sexual abuse 4. Prostate problems 5. Incontinence of bladder or bowels 6. Emotional problems like depression 7. Eating disorders 8. Alcohol or drug abuse 9. Birth control and sex (especially teens) 10. Menopause Preboth MA Am Fam Phys. 1999;59(1):18 Patient Misconceptions Sexual Health Issues • Poll of 500 US adults aged ≥25 years . 71% – thought clinician would dismiss sexual concerns . 68% – feared clinician embarrassement Marwick C. JAMA. 1999;281:2173-2174 Getting the Information: (Men or Women) [Whilst Perfecting ‘Swan Posture’] If you ask the “standard question”: “How is your sex life?” Getting the Information: (Men or Women) [Whilst Perfecting ‘Swan Posture’] You’ll get the “standard answer”: “fine” Getting the Information: (Men or Women) [Whilst Perfecting ‘Swan Posture’] With a twist on the standard: “How would you rate your sex life on a scale of 1–10?” Getting the Information: (Men or Women) [Whilst Perfecting ‘Swan Posture’] You’ll still likely get the politically correct: “Oh, about a 7…” Getting the Information So encourage them further by: “So what would have to be different to change it from a ‘7’ to a ‘10’?” Assume Swan Position NOW Swan Posture • More than once a year • 5 Times a Day • More than 1 minute • Less than 1 hour • After an Argument • After Drinking • Standing up in a Hammock The Universal-to-Specific Shepherding Technique Mr. Jones, many of my patients with _ (fill in the blank)_ notice changes in their sexual function; has this been an issue for you? Universal-to-Specific Technique Some Things that Go in the Blank • HTN • Depression • Hyperlipidemia • Sedentary • Smoking • Relationship conflict • Obesity • Meds • DM • Anxiety • Homocysteine↑ • Midlife and beyond Universal-to-Specific Shepherding Technique: Benefits • Informs: perhaps Jones didn’t know of the linkup between ‘X’ and sexual function • Informs: makes the relationship ‘common’ • Announces: clinician willing to address sex • Legitimizes: not just a QOL thing; disorder associated with recognized comorbidity Aging and Potency ∆ Prolongation of arousal phase ↑ Stimulation to arouse ↑ Refractory period ↓ Duration of orgasm ↓ or absent testicular elevation Galindo D. Patient Care. April 1995 Typical Patient Scenarios Complaint Scenario Timing Frequency Presenting ED main reason for 12-14 min Least Complaint visit Doorknob “Oh, by the way. .” 1-2 min Occasional Consultation During routine visit Ask for other medical Competing patient to problems, inquiry Most Complaint prioritize about sexual health uncovers ED 1-15 min Basic ED assessment is achievable during a standard office visit. How to Avoid “Oh by the way…” A Patient-Centered Introduction Clinician: “Hello, Mr. Jones. I see from your chart that you’re back for a recheck on your diabetes. Before we get started today, are there any other issues you’d like to bring up, so we can decide how we’re going to use our time today?” ED: Basic Evaluation .Targetted History .Targetted Physical Exam .Targetted Lab Targeted Medical Hx • Is it ED, or something else? • If it is ED, is it a problem? • Is it clearly psychogenic (eg. depression)? • Is there a clear secondary cause? . Meds (eg, SSRIs, thiazides) . Hypogonadism (Primary, chronic opioids) . Endothelial dysfunction (any vasculopathy) • Taking nitrates? ED Evaluation: Optional Basic Labs .Serum testosterone (A.M. best) .Serum lipids .Liver function tests .Serum creatinine .Glucose or HbA1c .Thyroid function tests .Prolactin Presenting Complaint: Successful Management • Targeted medical, sexual, psychosocial Hx . (Typically 4-6 min) • (Optional) PE of genitalia (2-4 mins) . Testes >2.5 cm . Peyronie’s . Sensation • Optional Lab (eg, TST,lipids, A1C) •Rx Total Time = 12 min Competing Complaint : Management • Solicit patient’s priority stratification • High priority: streamline plan as per presenting complaint = 7 to 15 min • Low priority: reschedule, provide education, and/or invitation for partner participation Doorknob Complaint:
Load more

Recommended publications
  • Phosphodiesterase-5 Inhibitors and the Heart: Heart: First Published As 10.1136/Heartjnl-2017-312865 on 8 March 2018
    Heart Online First, published on March 8, 2018 as 10.1136/heartjnl-2017-312865 Review Phosphodiesterase-5 inhibitors and the heart: Heart: first published as 10.1136/heartjnl-2017-312865 on 8 March 2018. Downloaded from compound cardioprotection? David Charles Hutchings, Simon George Anderson, Jessica L Caldwell, Andrew W Trafford Unit of Cardiac Physiology, ABSTRACT recently reported that PDE5i use in patients with Division of Cardiovascular Novel cardioprotective agents are needed in both type 2 diabetes (T2DM) and high cardiovascular Sciences, School of Medical risk was associated with reduced mortality.6 The Sciences, Faculty of Biology, heart failure (HF) and myocardial infarction. Increasing Medicine and Health, The evidence from cellular studies and animal models effect was stronger in patients with prior MI and University of Manchester, indicate protective effects of phosphodiesterase-5 was associated with reduced incidence of new MI, Manchester Academic Health (PDE5) inhibitors, drugs usually reserved as treatments of raising the possibility that PDE5is could prevent Science Centre, Manchester, UK erectile dysfunction and pulmonary arterial hypertension. both complications post-MI and future cardio- PDE5 inhibitors have been shown to improve vascular events. Subsequent similar findings were Correspondence to observed in a post-MI cohort showing PDE5i use Dr David Charles Hutchings, contractile function in systolic HF, regress left ventricular Institute of Cardiovascular hypertrophy, reduce myocardial infarct size and suppress was accompanied with reduced mortality and HF 7 Sciences, The University of ischaemia-induced ventricular arrhythmias. Underpinning hospitalisation. Potential for confounding in these Manchester, Manchester, M13 these actions are complex but increasingly understood observational studies is high, however, and data 9NT, UK; david.
    [Show full text]
  • Mechanisms of Action of PDE5 Inhibition in Erectile Dysfunction
    International Journal of Impotence Research (2004) 16, S4–S7 & 2004 Nature Publishing Group All rights reserved 0955-9930/04 $30.00 www.nature.com/ijir Original Research Mechanisms of action of PDE5 inhibition in erectile dysfunction JD Corbin1* 1Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennesse, USA A spinal reflex and the L-arginine–nitric oxide–guanylyl cyclase–cyclic guanosine monophosphate (cGMP) pathway mediate smooth muscle relaxation that results in penile erection. Nerves and endothelial cells directly release nitric oxide in the penis, where it stimulates guanylyl cyclase to produce cGMP and lowers intracellular calcium levels. This triggers relaxation of arterial and trabecular smooth muscle, leading to arterial dilatation, venous constriction, and erection. Phosphodiesterase 5 (PDE5) is the predominant phosphodiesterase in the corpus cavernosum. The catalytic site of PDE5 normally degrades cGMP, and PDE5 inhibitors such as sildenafil potentiate endogenous increases in cGMP by inhibiting its breakdown at the catalytic site. Phosphorylation of PDE5 increases its enzymatic activity as well as the affinity of its allosteric (noncatalytic/GAF domains) sites for cGMP. Binding of cGMP to the allosteric site further stimulates enzymatic activity. Thus phosphorylation of PDE5 and binding of cGMP to the noncatalytic sites mediate negative feedback regulation of the cGMP pathway. International Journal of Impotence Research (2004) 16, S4–S7. doi:10.1038/sj.ijir.3901205 Keywords: phosphodiesterase inhibitors; vasodilator agents; cyclic GMP; impotence; penile erection Introduction the tone of penile vasculature and the smooth muscle of the corpus cavernosum. In primates, including humans, the L-arginine– In recent years, a deeper understanding of the nitric oxide–guanylyl cyclase–cyclic guanosine regulation of penile smooth muscle has led to monophosphate (cGMP) pathway is the key me- greater insight into the physiology of normal erectile chanism of penile erection1–4 (Figure 1).
    [Show full text]
  • Caffeine and Adenosine
    Journal of Alzheimer’s Disease 20 (2010) S3–S15 S3 DOI 10.3233/JAD-2010-1379 IOS Press Review Article Caffeine and Adenosine Joaquim A. Ribeiro∗ and Ana M. Sebastiao˜ Institute of Pharmacology and Neurosciences, Faculty of Medicine and Unit of Neurosciences, Institute of Molecular Medicine, University of Lisbon, Lisbon, Portugal Abstract. Caffeine causes most of its biological effects via antagonizing all types of adenosine receptors (ARs): A1, A2A, A3, and A2B and, as does adenosine, exerts effects on neurons and glial cells of all brain areas. In consequence, caffeine, when acting as an AR antagonist, is doing the opposite of activation of adenosine receptors due to removal of endogenous adenosinergic tonus. Besides AR antagonism, xanthines, including caffeine, have other biological actions: they inhibit phosphodiesterases (PDEs) (e.g., PDE1, PDE4, PDE5), promote calcium release from intracellular stores, and interfere with GABA-A receptors. Caffeine, through antagonism of ARs, affects brain functions such as sleep, cognition, learning, and memory, and modifies brain dysfunctions and diseases: Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Epilepsy, Pain/Migraine, Depression, Schizophrenia. In conclusion, targeting approaches that involve ARs will enhance the possibilities to correct brain dysfunctions, via the universally consumed substance that is caffeine. Keywords: Adenosine, Alzheimer’s disease, anxiety, caffeine, cognition, Huntington’s disease, migraine, Parkinson’s disease, schizophrenia, sleep INTRODUCTION were considered out of the scope of the present work. For more detailed analysis of the actions of caffeine in Caffeine causes most of its biological effects via humans, namely cognition, dementia, and Alzheimer’s antagonizing all types of adenosine receptors (ARs).
    [Show full text]
  • Phosphodiesterase (PDE)
    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
    [Show full text]
  • Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction in Patients with Diabetes Mellitus
    International Journal of Impotence Research (2002) 14, 466–471 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus MA Vickers1,2* and R Satyanarayana1 1Department of Surgery, Togus VA Medical Center, Togus, Maine, USA; and 2Department of Surgery, Division of Urology, University of Massachusetts Medical School, Worcester, Massachusetts, USA Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, has become a first-line therapy for diabetic patients with erectile dysfunction (ED). The efficacy in this subgroup, based on the Global Efficacy Question, is 56% vs 84% in a selected group of non-diabetic men with ED. Two novel PDE5 inhibitors, tadalafil (Lilly ICOS) and vardenafil (Bayer), have recently completed efficacy and safety clinical trials in ‘general’ and diabetic study populations and are now candidates for US FDA approval. A summary analysis of the phase three clinical trials of sildenafil, tadalafil and vardenafil in both study populations is presented to provide a foundation on which the evaluation of the role of the individual PDE5 inhibitors for the treatment of patients with ED and DM can be built. International Journal of Impotence Research (2002) 14, 466–471. doi:10.1038=sj.ijir.3900910 Keywords: phosphodiesterase inhibitor; erectile dysfunction; diabetes mellitus; sildenafil; tadalafil; vardenafil Introduction (NO), vasointestinal peptide and prostacyclin, de- creases. Additionally, the endothelial cells that line the cavernosal arteries and sinusoids have a Pathophysiology of ED in diabetes decreased response to nitric oxide due to increased production of advanced glycation end-products and changes associated with insulin resistance.5,6 The Diabetes mellitus is a risk factor for erectile diabetic also experiences a decreased level of dysfunction (ED).
    [Show full text]
  • Alcohol-Induced Retrograde Memory Impairment in Rats: Prevention by Caffeine
    Psychopharmacology (2008) 201:361–371 DOI 10.1007/s00213-008-1294-5 ORIGINAL INVESTIGATION Alcohol-induced retrograde memory impairment in rats: prevention by caffeine Michael J. Spinetta & Martin T. Woodlee & Leila M. Feinberg & Chris Stroud & Kellan Schallert & Lawrence K. Cormack & Timothy Schallert Received: 26 March 2008 /Accepted: 30 July 2008 /Published online: 29 August 2008 # Springer-Verlag 2008 Abstract amnesia) to validate the test, 1.0 g/kg ethanol, or 3.0 g/kg Rationale Ethanol and caffeine are two of the most widely ethanol. The next day, they were presented again with N1 consumed drugs in the world, often used in the same setting. and also a bead from a new rat’scage(N2). Animal models may help to understand the conditions under Results Rats receiving saline or the lower dose of ethanol which incidental memories formed just before ethanol showed overnight memory for N1, indicated by preferential intoxication might be lost or become difficult to retrieve. exploration of N2 over N1. Rats receiving pentylenetetrazol Objectives Ethanol-induced retrograde amnesia was inves- or the higher dose of ethanol appeared not to remember N1, tigated using a new odor-recognition test. in that they showed equal exploration of N1 and N2. Materials and methods Rats thoroughly explored a wood Caffeine (5 mg/kg), delivered either 1 h after the higher bead taken from the cage of another rat, and habituated to dose of ethanol or 20 min prior to habituation to N1, this novel odor (N1) over three trials. Immediately following negated ethanol-induced impairment of memory for N1. A habituation, rats received saline, 25 mg/kg pentylenetetrazol combination of a phosphodiesterase-5 inhibitor and an (a seizure-producing agent known to cause retrograde adenosine A2A antagonist, mimicking two major mecha- nisms of action of caffeine, likewise prevented the memory impairment, though either drug alone had no such effect.
    [Show full text]
  • The Effects of the Combined Use of a PDE5 Inhibitor and Medications for Hypertension, Lower Urinary Tract Symptoms and Dyslipidemia on Corporal Tissue Tone
    International Journal of Impotence Research (2012) 24, 221 -- 227 & 2012 Macmillan Publishers Limited All rights reserved 0955-9930/12 www.nature.com/ijir ORIGINAL ARTICLE The effects of the combined use of a PDE5 inhibitor and medications for hypertension, lower urinary tract symptoms and dyslipidemia on corporal tissue tone JH Lee1,2, MR Chae1,2, JK Park1,3, JH Jeon1,4 and SW Lee1,2 ED is closely associated with its comorbidities (hypertension, dyslipidemia and lower urinary tract symptoms (LUTS)). Therefore, several drugs have been prescribed simultaneously with PDE5 inhibitors. If a specific medication for ED comorbidities has enhancing effects on PDE5 inhibitors, it offers alternative combination therapy in nonresponders to monotherapy with PDE5 inhibitors and allows clinicians to treat ED and its comorbidities simultaneously. To establish theoretical basis of choosing an appropriate medication for ED and concomitant disease, we examined the effects combining a PDE5 inhibitor with representative drugs for hypertension, dyslipidemia and LUTS on relaxing the corpus cavernosum of rabbits using the organ- bath technique. The effect of mirodenafil on relaxing phenylephrine-induced cavernosal contractions was significantly enhanced À4 À6 À6 À7 À9 by the presence of 10 M losartan, 10 M nifedipine, 10 M amlodipine, 10 M doxazosin and 10 M tamsulosin (Po0.05). The maximum relaxation effects were 47.2±3.8%, 57.6±2.6%, 64.0±3.7%, 76.1±5.7% and 71.7±5.4%, respectively. Enalapril and simvastatin had no enhancing effects. The relaxation induced by sodium nitroprusside alone (39.0±4.0%) was significantly À4 enhanced in the presence of the 10 M losartan (66.0±6.0%, Po0.05).
    [Show full text]
  • Gene Polymorphism on Response to Sildenafil Therapy In
    www.nature.com/scientificreports OPEN Efect of a phosphodiesterase-5A (PDE5A) gene polymorphism on response to sildenafl therapy in Received: 5 March 2019 Accepted: 18 April 2019 canine pulmonary hypertension Published: xx xx xxxx Yu Ueda, Lynelle R. Johnson, Eric S. Ontiveros, Lance C. Visser, Catherine T. Gunther-Harrington & Joshua A. Stern Pulmonary hypertension (PH) is a common clinical condition associated with morbidity and mortality in both humans and dogs. Sildenafl, a phosphodiesterase-5 (PDE5) inhibitor causing accumulation of cGMP, is frequently used for treatment of PH. The authors previously reported a PDE5A:E90K polymorphism in dogs that results in lower basal cyclic guanosine monophosphate (cGMP) concentrations than in wild-type dogs, which could contribute to variability in the efcacy of sildenafl. In this study, response to sildenafl therapy was evaluated in dogs with PH by comparing echocardiographic parameters, quality-of-life (QOL) score, and plasma cGMP concentrations before and after sildenafl therapy. Overall, tricuspid regurgitation estimated systolic pressure gradient (PG) and QOL score were signifcantly improved after sildenafl therapy, and the plasma cGMP concentration was signifcantly decreased. Dogs that had a heterozygous PDE5A status had a signifcantly worse QOL score when compared to the wildtype group after sildenafl treatment. The simple and multiple regression analyses revealed a signifcant but weak prediction for the percent reduction in QOL score with sildenafl treatment by plasma cGMP level and by the PDE5A:E90K polymorphic status. This study showed that sildenafl treatment improved PH in dogs, and the PDE5A:E90K polymorphism blunted the efcacy of sildenafl in terms of QOL improvement. Pulmonary hypertension (PH) is a pathologically complex condition characterized by abnormally increased pul- monary arterial (PA) pressure.
    [Show full text]
  • Clinical Pharmacology of Phosphodiesterase 5 Inhibitors in Erectile Dysfunction
    SOA Archives of Pharmacy & Pharmacology Review Article Clinical Pharmacology of Phosphodiesterase 5 Inhibitors in Erectile Dysfunction This article was published in the following Scient Open Access Journal: SOA Archives of Pharmacy & Pharmacology Received September 20, 2018; Accepted October 01, 2018; Published October 08, 2018 Michel Bourin* Abstract Department of pharmacology, University of Nantes, 98, rue Joseph Blanchart 44100 Nantes, France The drugs active on erectile dysfunction in humans are now mainly phosphodiesterase 5 inhibitors, those that are marketed are Sildenafil, Vardefanil, Taladafil, and Avanafil. We propose a synthesis of the pharmacological, pharmacokinetic and clinical properties of these derivatives. We have also listed their most common side effects and their potential drug interactions. Keywords: Phosphodiesterase 5 inhibitors, Sildenafil, Vardefanil, Taladafil, Avanafil. Introduction Phosphodiesterase 5 (PDE 5) inhibitors are a type of targeted therapy used to treat people with pulmonary hypertension (PH) [1]. Targeted therapies slow the progression of PH and may even reverse some of the damage to the heart and lungs. There are two typesPDE of PDE5 inhibitors 5 inhibitor are currentlyalso used usedto treat to treat erectile PH: dysfunction sildenafil, tadalafil [3]. This [2]. is because the body has the same type of cells in the blood vessels of the lungs as the blood vessels of the penis. Viagra (sildenafil) has been used to treat erectile problems since 1998. to obtain or maintain an erection. These problems are common and can be solved effectivelyIn case byof erectileconsulting dysfunction a doctor itand is essential following to a determine suitable treatment. the cause ofUnless the difficulties there are more serious causes of erectile dysfunction, the recommended treatment will usually be a PDE5 inhibitor.
    [Show full text]
  • PDE5 INHIBITOR POWDERS Sildenafil Powder, Tadalafil Powder
    PDE5 INHIBITOR POWDERS Sildenafil powder, Tadalafil powder RATIONALE FOR INCLUSION IN PA PROGRAM Background Sildenafil and Tadalafil are marketed as Revatio and Adcirca for pulmonary arterial hypertension. This is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence of left ventricular failure. This condition can progress to cause right-sided heart failure and death. Revatio and Adcirca received approval for treatment of pulmonary arterial hypertension (PAH) which is classified by WHO as Group 1. Revatio and Adcirca are used to treat pulmonary arterial hypertension (PAH, high blood pressure in the lungs) to improve the exercise ability. Tadalafil also comes as Cialis which is approved to treat the signs and symptoms of benign prostatic hyperplasia (BPH), a condition in which the prostate gland becomes enlarged (1-9). Sildenafil and Tadalafil, at different dosages, are also marketed as Viagra and Cialis respectively for the treatment of erectile dysfunction which is a plan exclusion (3-4). The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (5) WHO Group 1: Pulmonary Arterial Hypertension ( PAH) 1.1 Idiopathic (IPAH) 1.2 Heritable PAH 1.2.1 Germline mutations in the bone morphogenetic protein receptor type 2 (BMPR2) 1.2.2 Activin receptor-like kinase type 1 (ALK1), endoglin (with or without hereditary hemorrhagic telangiectasia), Smad 9, caveolin-1 (CAV1), potassium channel super family K member-3 (KCNK3) 1.2.3 Unknown 1.3 Drug-and toxin-induced 1.4 Associated with: 1.4.1 Connective tissue diseases 1.4.2 HIV infection 1.4.3 Portal hypertension 1.4.4 Congenital heart diseases PDE5 inhibitor powders FEP Clinical Rationale PDE5 INHIBITOR POWDERS Sildenafil powder, Tadalafil powder 1.4.5 Schistosomiasis 1'.
    [Show full text]
  • Cardiovascular Implications in the Use of PDE5 Inhibitor Therapy
    International Journal of Impotence Research (2004) 16, S20–S23 & 2004 Nature Publishing Group All rights reserved 0955-9930/04 $30.00 www.nature.com/ijir Cardiovascular implications in the use of PDE5 inhibitor therapy DH Maurice* Department of Pharmacology & Toxicology, Queen’s University at Kingston, Kingston, ON, Canada Cardiovascular smooth muscle cells (SMCs) exist as resting or activated cells. Resting SMCs produce contractile proteins and are nearly transcriptionally inactive; activated SMCs are transcriptionally active and are involved in pathological processes such as atherosclerosis. Soluble guanylate cyclase, protein kinase G, and protein kinase A are present in SMCs, but their levels can be decreased in activated cells. Phosphodiesterase 3 (PDE3) activity is abundant in cardiovascular tissues; both PDE3A and PDE3B are involved in cyclic adenosine monophosphate (cAMP) hydrolysis in these tissues. Cyclic-AMP-hydrolyzing PDE activities are altered during the phenotypic transition of SMCs from the resting to the activated phenotype. Similar changes have been observed in cyclic guanosine monophosphate cGMP-hydrolyzing PDEs, although the impact of these alterations on PDE5 inhibitor-mediated effects requires further study. This report presents the changes in PDE expression that accompany phenotypic modulation of SMCs and discusses the potential impact of these events on PDE5-mediated cell functions. International Journal of Impotence Research (2004) 16, S20–S23. doi:10.1038/sj.ijir.3901210 Keywords: phosphodiesterase; smooth muscle cells; cyclic AMP; cyclic GMP; protein kinase Introduction Quiescent/resting SMCs, normally present in healthy blood vessels that perfuse most organs, contract and relax in response to pulsatile differ- In addition to physiologically based differences in ences in the blood flow and in response to the the expression of individual phosphodiesterases pharmacologic and physiologic stimuli.
    [Show full text]
  • (Cgki) and PDE5 in the Regulation of Ang II-Induced Cardiac Hypertrophy and Fibrosis
    Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis Enrico Patruccoa, Katrin Domesa, Mauro Sbroggiób, Anne Blaicha, Jens Schlossmannc, Matthias Deschc, Sergei D. Rybalkind, Joseph A. Beavod,1, Robert Lukowskie, and Franz Hofmanna,1 aForschergruppe 923, Institut für Pharmakologie und Toxikologie, Technische Universität München, 80802 Munich, Germany; bCentro Nacional de Investigaciones Cardiovasculares, E-28029 Madrid, Spain; cLehrstuhl für Pharmakologie und Toxikologie, Institut für Pharmazie, Universität Regensburg, 93055 Regensburg, Germany; dDepartment of Pharmacology, University of Washington, Seattle, WA 98195-7280; and eInstitute of Pharmacy, Department of Pharmacology, Toxicology and Clinical Pharmacy, University of Tübingen, D-72076 Tübingen, Germany Contributed by Joseph A. Beavo, July 30, 2014 (sent for review May 15, 2014; reviewed by George W. Booz and Ali El-Armouche) Conflicting results have been reported for the roles of cGMP and hypertrophy gene response (8–11). Again, TRPC3 and TRPC6 cGMP-dependent protein kinase I (cGKI) in various pathological channels are negatively regulated by cGKI (12–14). conditions leading to cardiac hypertrophy and fibrosis. A cardio- It also has been reported that particulate guanylyl cyclase A, protective effect of cGMP/cGKI has been reported in whole the major receptor for atrial natriuretic peptide (ANP) in the animals and isolated cardiomyocytes, but recent evidence from heart, couples to and directly activates the TRPC3/C6 channels a mouse model expressing cGKIβ only in smooth muscle (βRM) but in chronic cardiac hypertrophy, thus bypassing cGMP and cGKI not in cardiomyocytes, endothelial cells, or fibroblasts has forced (15). It was reported that cardiac cGMP can affects cardiac a reevaluation of the requirement for cGKI activity in the cardio- properties by modulating cAMP levels, bypassing again cGKI myocyte antihypertrophic effects of cGMP.
    [Show full text]